About Daré Bioscience, Inc.
https://www.darebioscience.comDaré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health.
CEO
Sabrina Martucci Johnson
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-07-01 | Reverse | 1:12 |
| 2017-07-20 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:394.9K
Value:$801.64K
POLARIS VENTURE MANAGEMENT CO. V, L.L.C.
Shares:326.24K
Value:$662.27K
AMH EQUITY LTD
Shares:232.37K
Value:$471.72K
Summary
Showing Top 3 of 28
About Daré Bioscience, Inc.
https://www.darebioscience.comDaré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.26K ▲ | $3.06M ▼ | $-3.56M ▲ | -157.51K% ▼ | $-0.28 ▲ | $-2.74M ▲ |
| Q2-2025 | $-21.17K ▼ | $3.81M ▲ | $-4.02M ▲ | 18.97K% ▲ | $-0.45 ▲ | $-3.37M ▲ |
| Q1-2025 | $25.43K ▲ | $2.31M ▲ | $-4.38M ▲ | -17.22K% ▼ | $-0.5 ▲ | $-4.42M ▲ |
| Q4-2024 | $-63.65K ▼ | $-8.9M ▼ | $-5.51M ▼ | 8.65K% ▲ | $-0.65 ▼ | $-5.38M ▼ |
| Q3-2024 | $41.69K | $4.7M | $-4.7M | -11.28K% | $-0.55 | $-4.67M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $23.08M ▲ | $30.75M ▲ | $27.89M ▲ | $2.86M ▲ |
| Q2-2025 | $5.04M ▼ | $12.98M ▼ | $25.71M ▼ | $-12.73M ▼ |
| Q1-2025 | $10.33M ▼ | $18.62M ▼ | $28.18M ▲ | $-9.56M ▼ |
| Q4-2024 | $15.7M ▲ | $22.1M ▲ | $28.11M ▲ | $-6.01M ▼ |
| Q3-2024 | $11.23M | $18.06M | $19.54M | $-1.48M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.56M ▲ | $-442.13K ▲ | $-174.7K ▼ | $18.65M ▲ | $18.04M ▲ | $-616.84K ▲ |
| Q2-2025 | $-4.02M ▲ | $-5.42M ▲ | $153.4K ▲ | $-43.79K ▼ | $-5.29M ▲ | $-5.26M ▲ |
| Q1-2025 | $-4.38M ▲ | $-5.47M ▼ | $-157.33K ▲ | $246.58K ▲ | $-5.37M ▼ | $-5.63M ▼ |
| Q4-2024 | $-5.51M ▼ | $5.23M ▲ | $-562.85K ▼ | $-132.01K ▼ | $4.47M ▲ | $4.66M ▲ |
| Q3-2024 | $-4.7M | $-5.92M | $282.32K | $436.44K | $-5.18M | $-5.64M |
Revenue by Products
| Product | Q2-2024 | Q3-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 License And Collaboration Revenue | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
Sabrina Martucci Johnson
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-07-01 | Reverse | 1:12 |
| 2017-07-20 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:394.9K
Value:$801.64K
POLARIS VENTURE MANAGEMENT CO. V, L.L.C.
Shares:326.24K
Value:$662.27K
AMH EQUITY LTD
Shares:232.37K
Value:$471.72K
Summary
Showing Top 3 of 28